Sanifit raise 72.2m to push SNF472 development
Sanifit has bagged 72.2m in Spains largest private biotech fundraise.
Sanifit has bagged 72.2m in Spains largest private biotech fundraise.
Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.
Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at 120m.
Erytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies.
Sanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients.
Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (141m).
German GM proponents have taken action against discrimination of food products generated by gene editing.
Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the companys inception in 2017.
Researchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone.
Scientists from the University of Washington are using the Phenoglyphs machine learning module to achieve faster high-content analysis through automation and simplification.